Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Redeye: BeammWave (Q3 Review) - Period of digestion

BeammWave

Redeye notes that BeammWave’s Q3 2025 report was in line with its EBITDA forecast, due to OPEX being 10% lower than expected, although capitalised costs were SEK0.9m below forecast. Following a capital raise that netted SEK79m, BeammWave holds a cash position of SEK93m. Redeye believes news flow will be limited ahead of the tape-out, as the company focuses on supporting existing customers, advancing its roadmap, and completing the chip's industrialisation. Redeye adjusts its Base Case from SEK12 to SEK11.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


BeammWave (Q3 Review) - Period of digestion

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.